EN DE
Watch GUJARAT THEMIS BIOSYN LTD. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of GUJARAT THEMIS BIOSYN LTD. stock ₹69.74, price ₹389, that is 82.1% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE942C01029

GT GUJARAT THEMIS BIOSYN LTD. logo Thin data Nov 11, 2026

GUJARAT THEMIS BIOSYN LTD.

GUJTHEM · BSE

Far too expensive (fair value 82% below the price), company just short of the bar and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Highly profitable · 28.0% net margin (TTM) 
Low debt 
Revenue last quarter +22% vs. a year ago. 
Quality 51/100 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +12.9 %/yr in INR) 
0.2% dividend yield · Token dividend
Wide moat 77/100 · thin data
Fair value ₹69.74 · Strongly overvalued 
Negative free cash flow 
Trails peers (5/13) 
Thin data 
Extreme value
Watch GUJARAT THEMIS BIOSYN LTD. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹472.70 ₹32.27 Fair Value ₹69.74 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range ₹32.27 – ₹472.70 · fair‑value band ₹49.29 – ₹90.18 · the ₹389.25 price screens above the ₹69.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow GUJARAT THEMIS BIOSYN in your weekly email

Every Wednesday you see whether GUJARAT THEMIS BIOSYN is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin.

Show moreShow less

The company was incorporated in 1981 and is based in Mumbai, India.

Stock analysis

GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) currently trades at ₹389.25, while our model-based Fair Value estimate is ₹69.74, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹70.42 per share, and 0 of the 16 models we run sit above the ₹389.25 price.

Bear case: the Asset-Based group reads lowest at ₹14.81, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹49.29 (bear) to ₹90.18 (bull), the price of ₹389.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

GUJARAT THEMIS BIOSYN LTD. reported revenue of ₹1.7B in FY2026 versus ₹1.1B in FY2022, a compound +9.8%/yr. Reported net income was ₹467M in FY2026, compounding +1.7%/yr from FY2022.

Key figures

Market cap ₹50.3B (≈ $533M) Small · P/E ratio 87.1 · P/S ratio 28.9 · EPS (TTM) ₹4.47 · Dividend yield 0.2% · Net margin 28.0% · Return on equity 17.4% · Return on assets (EBIT) 31.5% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −82%, GUJTHEM screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹6.15 to ₹114.62). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹49.29 Fair Value ₹69.74 Bull ₹90.18
Price ₹389.25 · Downside -82.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹2.39 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹20.49 ₹24.90 ₹36.26 75
EPV ₹20.39 ₹23.97 ₹26.86 74
ROIC Compounder ₹20.39 ₹25.40 ₹32.63 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹24.39 ₹114.62 ₹157.57 64
Lynch FV ₹33.32 ₹47.60 ₹61.87 61
PEG = 1.0 ₹33.32 ₹47.60 ₹61.87 57
EPV ₹20.39 ₹23.97 ₹26.86 74
Dividend Discount
Gordon GGM ₹3.88 ₹6.47 ₹8.38 68
DDM Multi-Stage ₹3.88 ₹6.15 ₹6.97 67
Multiples
P/E Multiple ₹59.19 ₹78.92 ₹98.64 63
P/S Multiple ₹33.44 ₹44.59 ₹55.74 58
P/B Multiple ₹74.60 ₹99.46 ₹124.33 55
EV/EBIT ₹49.29 ₹69.74 ₹90.18 65
EV/EBITDA ₹48.89 ₹69.20 ₹89.51 67
EV/Revenue ₹14.71 ₹26.18 ₹37.65 52
Asset-Based
NCAV (Graham) ₹11.05 ₹14.81 ₹22.10 54
Economic Profit
Residual Income ₹20.49 ₹24.90 ₹36.26 75
ROIC Compounder ₹20.39 ₹25.40 ₹32.63 72
Growth Earnings
Growth-Adj P/E ₹49.30 ₹70.42 ₹91.55 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 58
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 34
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 57
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 47
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 60/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.4%
Dividend (yield on the price)0.2%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.44% → 38%
⚠ Revenue per share shrinking 11.6%/yr over ~5Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

GUJTHEM screens overvalued: fair value 82% below the price. Compare with Merck KGaA →

Compare GUJARAT THEMIS BIOSYN LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 603 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside −82.1% · Bottom 25%
Profitability
Return on equity (12 months) 17.4% · Top 25%
Return on assets 9.3% · Top 25%
Net margin (12 months) 28.0% · Top 25%
Operating margin (12 months) 38.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 22.1% · Top 25%
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.45× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 87.1× · Priciest 25%
P/B 17.47× · Priciest 25%
P/S (12 months) 28.93× · Priciest 25%
EV/EBITDA 62.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 26
PAST (return on equity)70 · sector 25
HEALTH (low debt)78 · sector 96
DIVIDEND (yield)3 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs GUJTHEM
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs GUJTHEM
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs GUJTHEM
Haleon plc HLN $9.17 $8.47 −8% vs GUJTHEM
Merck KGaA MRK €149.60 €108.83 −27% vs GUJTHEM
Galderma Group GALD CHF 191.40 CHF 112.30 −41% vs GUJTHEM
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs GUJTHEM
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs GUJTHEM
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs GUJTHEM
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs GUJTHEM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GUJARAT THEMIS BIOSYN LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GUJARAT THEMIS BIOSYN LTD. Fair Value". https://www.fairvalue-calculator.com/stock/GUJTHEM

Frequently asked questions

Is GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹69.74 versus a price of ₹389.25, about 82% lower (overvalued).
What is the fair value of GUJTHEM?
Our model-based fair value for GUJARAT THEMIS BIOSYN LTD. is ₹69.74 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹389.25.
What is the quality score of GUJTHEM?
GUJARAT THEMIS BIOSYN LTD. has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Our model-based price target is the fair value of ₹69.74 (as of Nov 11, 2026) from 16 valuation models. Cautious scenario ₹49.29, optimistic scenario ₹90.18. It is a calculation from audited fundamentals, not an analyst target.
What is the GUJARAT THEMIS BIOSYN LTD. stock forecast for 2026?
Our models put fair value at ₹69.74, about 82% lower versus a price of ₹389.25 (overvalued). Cautious scenario ₹49.29, optimistic scenario ₹90.18. The calculation is refreshed regularly with new filings.
What is the revenue of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
GUJARAT THEMIS BIOSYN LTD. reported trailing-twelve-month revenue of about ₹1.7B (latest available figure, as of Nov 11, 2026).
Does GUJARAT THEMIS BIOSYN LTD. pay a dividend?
GUJARAT THEMIS BIOSYN LTD. currently shows a dividend yield of 0.17% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) and when is the ex-dividend date?
GUJARAT THEMIS BIOSYN LTD. pays a dividend of ₹0.67 per share a year, a dividend yield of 0.2%. The last ex-dividend date was Sep 23, 2026. A dividend has been paid every year since at least 2020. The payout ratio is 15.0% of earnings. Our assessment: Token dividend. At a yield of 0.2% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.2% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GUJARAT THEMIS BIOSYN LTD. it is ₹69.74 per share (as of Nov 11, 2026), against a price of ₹389.25. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is GUJARAT THEMIS BIOSYN LTD. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, GUJTHEM trades above its calculated fair value: price ₹389.25, fair value ₹69.74, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GUJTHEM?
No. The price is what the market pays today (₹389.25); the fair value is what the company's own numbers justify (₹69.74). For GUJARAT THEMIS BIOSYN LTD. the two are ₹319.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is GUJARAT THEMIS BIOSYN LTD. worth?
The market values GUJARAT THEMIS BIOSYN LTD. at about ₹50.3B (market capitalisation, as of Nov 11, 2026). Per share that is ₹389.25; our models calculate a fair value of ₹69.74 per share.
What do the bullish and bearish scenarios say about GUJTHEM?
Our models span a range for GUJARAT THEMIS BIOSYN LTD.: cautious scenario ₹49.29, base ₹69.74, optimistic ₹90.18 per share (as of Nov 11, 2026, price ₹389.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GUJTHEM?
GUJARAT THEMIS BIOSYN LTD. trades at a price-to-earnings ratio of 87.1 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹69.74 is built from several models across several years. Other multiples: P/B 17.5, P/S 28.9, EV/EBITDA 62.3.
How solid is the balance sheet of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Balance-sheet figures for GUJARAT THEMIS BIOSYN LTD. (as of Nov 11, 2026): return on equity 17.4%, debt of 0.45 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is GUJTHEM from its 52-week high?
GUJARAT THEMIS BIOSYN LTD. trades at ₹389.25, about 14% below its 52-week high of ₹453.10 and 71% above the low of ₹227.45 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹69.74 is for.
Which stocks are comparable to GUJARAT THEMIS BIOSYN LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GUJARAT THEMIS BIOSYN LTD. stock attractive at the current price?
The data as of Nov 11, 2026: price ₹389.25, calculated fair value ₹69.74 (−82%), Quality Score 51/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GUJTHEM calculated?
We run GUJARAT THEMIS BIOSYN LTD. through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹69.74 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. GUJARAT THEMIS BIOSYN LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The closing price on Nov 13, 2026 was ₹389.25. Our model-based fair value is ₹69.74, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GUJARAT THEMIS BIOSYN LTD. right now?
The price sits above even our optimistic bull case (₹90.18). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹49.29 to ₹90.18) leaves room in how you read the outcome.

Key figures of GUJARAT THEMIS BIOSYN LTD.

How large is the market capitalisation of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The market capitalisation of GUJARAT THEMIS BIOSYN LTD. is ₹50.3B (≈ $533M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The price-to-sales ratio of GUJARAT THEMIS BIOSYN LTD. is 28.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Earnings per share at GUJARAT THEMIS BIOSYN LTD. are ₹4.47 (price ÷ EPS = P/E 87.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The dividend yield of GUJARAT THEMIS BIOSYN LTD. is 0.2% (payout 15.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The net margin of GUJARAT THEMIS BIOSYN LTD. is 28.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The return on equity (ROE) of GUJARAT THEMIS BIOSYN LTD. is 17.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
On an EBIT basis the return on assets of GUJARAT THEMIS BIOSYN LTD. is 31.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
The operating margin of GUJARAT THEMIS BIOSYN LTD. is 38.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Revenue at GUJARAT THEMIS BIOSYN LTD. is growing 22.1% versus a year earlier (3y avg +3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Earnings per share at GUJARAT THEMIS BIOSYN LTD. are growing 22.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) generate?
The free cash flow of GUJARAT THEMIS BIOSYN LTD. is −₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) carry?
The net debt of GUJARAT THEMIS BIOSYN LTD. is ₹1.6B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GUJARAT THEMIS BIOSYN LTD. in the live analysis

One click puts GUJARAT THEMIS BIOSYN LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.